Canaccord lowered the firm’s price target on BioMarin to $112 from $119 and keeps a Hold rating on the shares. The analyst said following the early Jan pre-announcement, much of its 4Q report was uneventful. Canaccord said the pipeline front, timelines around progress and upcoming events are on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin price target raised to $127 from $110 at Credit Suisse
- BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61
- BioMarin reports Q4 EPS (0c), consensus (7c)
- BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
- Notable companies reporting after market close